Picture loading failed.

Anti-DPP4 therapeutic antibody (Pre-made Begelomab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

A monoclonal antibody against the human dipeptidyl peptidase 4 (dipeptidylpeptidase IV, DPPIV, DPP4; CD26), with potential activity against graft-versus-host disease (GvHD). Upon administration, begelomab binds to CD26 expressed on T-cells. This inhibits the stimulation of T-cells and may prevent GvHD.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-054-1mg 1mg 3090
GMP-Bios-ab-054-10mg 10mg 21890
GMP-Bios-ab-054-100mg 100mg 148000
GMP-Bios-ab-054-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-DPP4 therapeutic antibody (Pre-made Begelomab biosimilar,Whole mAb)
INN Name Begelomab
TargetDPP4
FormatWhole mAb
DerivationMouse
Species ReactivityHuman
CH1 IsotypeIgG2b
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II/III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesADIENNE
Conditions Approvedna
Conditions ActiveGraft-versus-host disease
Conditions Discontinuedna
Development Techna